Physician profile
Jonathan P Forman
NPI 1861493926
$7,388.09
in general payments reported to CMS, 2019-2025
51 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,697 · 2020: $1,884 · 2021: $1,760 · 2022: $2,010 · 2023: $37.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $942.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $644.28 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.73 | 2019-2022 | |
| Lilly USA, LLC | $423.78 | 2019-2022 | |
| Pfizer INC. | $408.22 | 2019-2022 | |
| Abbvie INC. | $391.92 | 2020-2022 | |
| Allergan, INC. | $372.92 | 2019-2020 | |
| Amgen INC. | $366.18 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $358.07 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $292.67 | 2019-2022 | |
| Daiichi Sankyo INC. | $258.96 | 2019-2023 | Injectafer |
| Viiv Healthcare Company | $218.72 | 2020 | |
| Janssen Pharmaceuticals, INC | $214.18 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $199.94 | 2019-2022 | |
| Glaxosmithkline, LLC. | $194.19 | 2020-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Forman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.